Proteostasis Therapeutics (NASDAQ:PTI) had its price target hoisted by investment analysts at Leerink Swann from $6.00 to $8.00 in a report released on Tuesday. Leerink Swann’s target price would indicate a potential upside of 46.25% from the stock’s current price. Leerink Swann also issued estimates for Proteostasis Therapeutics’ Q1 2018 earnings at ($0.49) EPS, Q2 2018 earnings at ($0.48) EPS, Q3 2018 earnings at ($0.46) EPS, Q4 2018 earnings at ($0.47) EPS, FY2018 earnings at ($1.89) EPS, FY2019 earnings at ($1.52) EPS and FY2020 earnings at ($1.57) EPS.
PTI has been the subject of a number of other reports. Robert W. Baird boosted their price objective on shares of Proteostasis Therapeutics from $13.00 to $25.00 and gave the stock an “outperform” rating in a report on Tuesday. Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 18th.
Shares of Proteostasis Therapeutics (NASDAQ:PTI) traded down $0.67 during midday trading on Tuesday, reaching $5.47. 4,317,800 shares of the company were exchanged, compared to its average volume of 316,455. Proteostasis Therapeutics has a 52 week low of $1.41 and a 52 week high of $16.67.
A number of large investors have recently bought and sold shares of the business. LMR Partners LLP bought a new stake in Proteostasis Therapeutics in the 2nd quarter worth approximately $127,000. Goldman Sachs Group Inc. grew its position in Proteostasis Therapeutics by 364.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 51,911 shares of the company’s stock worth $243,000 after purchasing an additional 40,731 shares during the period. Susquehanna International Group LLP bought a new stake in Proteostasis Therapeutics in the 2nd quarter worth approximately $254,000. Dimensional Fund Advisors LP bought a new stake in Proteostasis Therapeutics in the 2nd quarter worth approximately $296,000. Finally, Sabby Management LLC grew its position in Proteostasis Therapeutics by 109.6% in the 2nd quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock worth $586,000 after purchasing an additional 65,451 shares during the period. 68.08% of the stock is owned by institutional investors and hedge funds.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.